What cagrilintide is and how it works
Cagrilintide is a long‑acting analogue of amylin, a hormone co‑secreted with insulin. Amylin helps regulate appetite and meal size by promoting satiety, slowing gastric emptying, and acting on brain regions involved in hunger control. By mimicking amylin’s effects, cagrilintide aims to reduce energy intake and support clinically meaningful weight loss in people with overweight or obesity.
In several studies, cagrilintide has also been evaluated in combination with semaglutide (a GLP‑1 receptor agonist). Because amylin and GLP‑1 pathways are complementary, many readers encounter the term “CagriSema” when researching cagrilintide for obesity.
What the evidence shows so far
Human phase 2 trials reported that:
- Cagrilintide alone produced clinically meaningful average weight loss compared with placebo over study durations typical of early obesity trials.
- Combining cagrilintide with semaglutide (CagriSema) led to greater average weight loss than either medicine alone over matched time frames.
- Participants also showed improvements in secondary metabolic measures in some studies (such as waist circumference, blood pressure, lipids, or glycaemic markers), though the magnitude and consistency vary across trials.
These results established a rationale for larger phase 3 programs now underway internationally to confirm longer‑term effectiveness and safety. Until those readouts are complete and regulators review the data, cagrilintide remains an investigational option.
See potential benefits and study snapshots Ask a specialist team a question
How it compares with GLP‑1 options and other emerging agents
GLP‑1 receptor agonists (for example, semaglutide) reduce appetite and improve metabolic regulation through incretin signalling. Cagrilintide targets the amylin pathway, which reinforces satiety and slows gastric emptying. Early data suggest these pathways are complementary, which explains why combination regimens have shown larger average weight loss than monotherapy in phase 2 research.
- Cagrilintide vs Semaglutide: Satiety‑focused amylin analogue vs incretin‑based GLP‑1.
- Cagrilintide vs Tirzepatide: Appetite control via amylin vs dual GLP‑1/GIP agonism.
- Retatrutide for Obesity: Triple agonist research many readers compare when exploring next‑gen options.
If you are deciding where to focus reading time, start with the approved GLP‑1 landscape, then branch into investigational combinations:
How cagrilintide has been used in studies
Trials have evaluated once‑weekly subcutaneous injections with dose escalation to improve tolerability. In combination studies, semaglutide followed its standard titration schedule while cagrilintide was up‑titrated in parallel. Doses, escalation speed, and total duration varied across protocols.
Because products and strengths used in research are investigational and not commercially available in Australia, any use outside a trial would require an authorised prescriber, appropriate approvals, and careful monitoring.
Safety and side effects to know about
The most common side effects reported with cagrilintide (and with GLP‑1 combinations) are gastrointestinal, particularly during early dose escalation:
- Nausea, vomiting, constipation, abdominal discomfort or diarrhoea
- Reduced appetite and delayed gastric emptying
- Injection‑site reactions
Important cautions discussed in obesity medicine include: suitability in people with significant gastrointestinal disease (e.g., gastroparesis), a history of pancreatitis, gallbladder disease risk, interactions with other glucose‑lowering therapies, and use in pregnancy or breastfeeding. Individual risk varies and needs medical review.
Read the side effects and warning guide Get help assessing suitability
Access and legality in Australia
As of the latest public updates, cagrilintide and the fixed‑dose combination with semaglutide are not approved by the Therapeutic Goods Administration (TGA) for obesity. Access is typically limited to:
- Participation in registered clinical trials
- Unapproved‑product pathways at a doctor’s discretion (e.g., the TGA Special Access Scheme or Authorised Prescriber frameworks), where appropriate and lawful
Be cautious with websites advertising “research peptides” or claiming easy retail access. Importing, supplying, or using unapproved medicines outside Australia’s regulatory pathways can be unlawful and risky.
Is cagrilintide legal in Australia? Safer access and red‑flag checklist
Who this research may be for
Trials typically enrol adults with overweight or obesity, sometimes including people with type 2 diabetes. If you are comparing options after trying lifestyle strategies, your clinician may suggest starting with approved GLP‑1 therapies first, then discussing investigational pathways or clinical trials if appropriate.
How long results may take
In clinical studies, weight typically declined over weeks to months with continued treatment and dose escalation. The combination with semaglutide showed earlier and larger average reductions than monotherapy in matched time frames. Individual responses vary widely based on dose, tolerability, adherence, baseline weight, behaviour changes, and comorbidities.
Cagrilintide results timeline Ask about realistic expectations
Frequently asked questions
Is cagrilintide approved for obesity in Australia?
No. It is investigational. Routine prescribing is not available, and access is generally limited to clinical trials or regulated unapproved‑product pathways.
How much weight loss has been seen?
Phase 2 studies reported clinically meaningful average weight loss with cagrilintide alone and greater average loss with cagrilintide plus semaglutide versus either alone. Exact percentages depend on dose and duration.
Can it be combined with semaglutide?
Yes, this has been studied. The fixed‑dose combination is investigational and is often referred to as CagriSema in research updates.
What side effects should I expect?
Mostly gastrointestinal effects (nausea, vomiting, constipation), often improving with gradual dose escalation. Discuss risks such as gallbladder issues and pancreatitis history with a clinician.
Who should avoid it?
People with significant gastrointestinal disorders (e.g., gastroparesis), those who are pregnant or breastfeeding, and individuals with certain medical histories may not be suitable. Only a qualified prescriber can advise.
How is it taken?
Once‑weekly subcutaneous injection in studies, with dose escalation for tolerability. Protocols differ across trials.
How quickly might I notice changes?
Studies show progressive changes over weeks to months with titration and adherence. The combination with semaglutide tends to produce larger changes over matched periods than monotherapy.
What should I read next?
Start with the focused pages below, or ask a question using the form.
Key takeaways
- Cagrilintide is an amylin analogue being studied for obesity, often alongside semaglutide.
- Phase 2 data show meaningful average weight loss; combinations have outperformed single agents in matched study windows.
- Gastrointestinal effects are the most common side effects; careful titration helps tolerability.
- It is not TGA‑approved for obesity at this time; access is primarily via trials or regulated unapproved‑product pathways.
Ask a question about cagrilintide for obesity
Send your question and we’ll reply with evidence‑based information and links to relevant Australian guidance. This is general information, not medical advice.
Prefer to browse? Explore the cagrilintide hub: What is cagrilintide?, Benefits, Side effects, Legal status.